Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease"
- PMID: 35980034
- PMCID: PMC9756875
- DOI: 10.1002/mds.29131
Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease"
Comment on
-
No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.Mov Disord. 2022 Mar;37(3):653. doi: 10.1002/mds.28935. Epub 2022 Jan 24. Mov Disord. 2022. PMID: 35075696 Free PMC article. No abstract available.
-
Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations?Mov Disord. 2022 Aug;37(8):1779-1781. doi: 10.1002/mds.29132. Epub 2022 Jul 6. Mov Disord. 2022. PMID: 35792565 No abstract available.
References
-
- Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, Hsieh T, Song L, Padmanabhan S, Hsieh F, Merchant KM, Alcalay RN. Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson’s Disease. Mov Disord. 2021. Epub 2021/11/07. doi: 10.1002/mds.28846. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical